Geographic Atrophy

David S. Boyer, MD, senior partner at Retina Vitreous Associates Medical Group, shares key takeaways from "Advances in geographic atrophy," which he co-presented.

Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).

Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.

Apellis Pharmaceuticals Inc. delivered an oral presentation at the ARVO Annual Meeting in New Orleans announcing their post hoc analyses from the Phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy (GA).

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

Researchers conducted clinical imaging and histopathologic studies to gain a better understanding of geographic atrophy (GA) in 3 siblings.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

Imaging biomarkers are useful to determine the degree of EZ attenuation in the fovea.

Industry leaders view pegcetacoplan as most important retinal technology in 10 years.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

Ophthalmologists see new therapy as having a major impact on how geographic atrophy is treated.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.

A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.